Lower-Dose drug could make Life-Saving transplants safer and more accessible

This study tested whether a lower dose of a drug called cyclophosphamide could effectively prevent a serious complication called graft-versus-host disease (GVHD) after a stem cell transplant. The trial involved 35 adults with blood cancers or disorders who received a transplant from a related donor. Researchers aimed to see if the lower dose could control GVHD as well as the standard dose while potentially helping patients recover their blood counts faster and reducing treatment costs.